Skip to content
Biodatica
Start free

Investigator

Worapol Ngamcherdtrakul

PDX PHARMACEUTICALS, INC. · funded by NCI

Companies
1

Resolved onto their grants.

Grants
2

Federal awards on file.

Non-dilutive funding
$1.4M

Summed across those awards.

First award
Jul 6, 2023

Latest Sep 5, 2024.

Companies from this work

Pre-ticker companies the crosswalk resolved onto a grant filed under this investigator. Momentum shows for the therapeutic areas your seat covers; open a dossier for the full crosswalk.

Grant record

Federal awards filed under this investigator name, newest first. Each links to the public record where the awarding agency publishes one.

  1. SB1

    Advancing the commercialization readiness of nanoparticle-based immunotherapy for cancer treatment

    $89k

    Sep 5, 2024NCIPDX PHARMACEUTICALS, INC.NIH RePORTER · 11184418 (opens the source filing in a new tab)

  2. R44

    PLK1 and EGFR targeted nanoconstruct as a monotherapy and a radiation sensitizer for lung cancer

    $1.3M

    Jul 6, 2023NCIPDX PHARMACEUTICALS, INC.NIH RePORTER · 11179339 (opens the source filing in a new tab)

This page aggregates public U.S. federal grant records filed under one investigator name and the companies Biodatica has resolved onto them. Names are shown as the awarding agency filed them; grant awards are non-dilutive federal funding, not equity or valuation. Distinct people who file under the same name would appear together here. It is informational only and not investment advice. Methodology · Data sources